Aug 13 (Reuters) -
RESPONSE PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF RDX-002 IN POST-GLP-1 MANAGEMENT
RESPONSE PHARMACEUTICALS: STUDY'S PRIMARY ENDPOINT MET
RESPONSE PHARMACEUTICALS: STUDY'S MULTIPLE SECONDARY ENDPOINTS MET INCLUDING STATISTICALLY SIGNIFICANT REDUCTION IN WEIGHT REGAIN (-34%) VERSUS PLACEBO